[{"from": "human", "value": "Describe this molecule. [C][N][Branch1][C][C][C][C][C][=C][N][C][=C][Ring1][Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][C@H1][C][O][C][=Branch1][C][=O][N][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine. [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan. Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current \"gold standard\" for acute migraine treatment.  Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig\u00ae on November 25, 1997. It is currently available in both tablet and nasal spray forms."}]